MedTrace Logo

Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma

NCT01052142 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2012-04-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is safe and effective in improving the body's ability to destroy cancer cells in patients with metastatic melanoma.

Conditions

Interventions

BIOLOGICAL

Lipovaxin-MM

Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals

Sponsors & Collaborators

  • Royal Adelaide Hospital

    collaborator OTHER

  • Trident Clinical Research Pty Ltd

    collaborator INDUSTRY

  • Lipotek Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Michael Brown, MBBS FRACP FRCPA · Royal Adelaide Hospital Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01052142 on ClinicalTrials.gov